This is therefore a contrasting of the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation in CRISPR Therapeutics AG (NASDAQ:CRSP) and Rigel Pharmaceuticals Inc. (NASDAQ:RIGL). The two are both Biotechnology companies that compete with one another.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||49||0.00||34.37M||-3.74||0.00|
|Rigel Pharmaceuticals Inc.||2||-0.08||158.39M||-0.39||0.00|
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 hightlights the return on equity, net margins and return on assets of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||69,603,078.17%||-50.9%||-39.8%|
|Rigel Pharmaceuticals Inc.||7,689,954,847.79%||-58.9%||-44.2%|
The current Quick Ratio of CRISPR Therapeutics AG is 15.8 while its Current Ratio is 15.8. Meanwhile, Rigel Pharmaceuticals Inc. has a Current Ratio of 5.3 while its Quick Ratio is 5.3. CRISPR Therapeutics AG is better positioned to pay off its short-term and long-term debts than Rigel Pharmaceuticals Inc.
Ratings and Recommendations for CRISPR Therapeutics AG and Rigel Pharmaceuticals Inc. can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||4||3.00|
|Rigel Pharmaceuticals Inc.||0||0||3||3.00|
CRISPR Therapeutics AG’s average price target is $66.5, while its potential downside is -2.36%. Rigel Pharmaceuticals Inc. on the other hand boasts of a $6.67 average price target and a 181.43% potential upside. The results from earlier shows that analysts opinion suggest that Rigel Pharmaceuticals Inc. seems more appealing than CRISPR Therapeutics AG.
Institutional and Insider Ownership
CRISPR Therapeutics AG and Rigel Pharmaceuticals Inc. has shares held by institutional investors as follows: 50% and 96.2%. Insiders held roughly 2% of CRISPR Therapeutics AG’s shares. Competitively, Rigel Pharmaceuticals Inc. has 0.25% of it’s share held by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||3.15%||6.25%||30.58%||57.23%||7.51%||77.42%|
|Rigel Pharmaceuticals Inc.||-6.94%||-9.88%||3.17%||5.07%||-17.99%||-0.87%|
For the past year CRISPR Therapeutics AG had bullish trend while Rigel Pharmaceuticals Inc. had bearish trend.
CRISPR Therapeutics AG beats Rigel Pharmaceuticals Inc. on 6 of the 11 factors.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and Daiichi Sankyo to pursue research related to ligases. The company was founded in 1996 and is based in South San Francisco, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.